Parkinson Disease Panel
Use
This test is designed for individuals with relevant features who have a clinical or suspected diagnosis of Parkinson disease. It is suitable for individuals with any age of onset: infantile, juvenile, early-onset, or late-onset Parkinson disease. The panel is comprehensive, covering 24 genes associated with Parkinson's disease, which makes it useful for diagnosing and managing patients by identifying potential genetic causes.
Special Instructions
The test can be performed using NGS with CNV on either Exome or Genome platforms. Different specimen types may be required depending on the platform used. The test offers additional order options such as STAT testing for faster results and exome-wide CNV analysis as an add-on. Standard institutional pricing is available upon signing in, and the test is New York approved, ensuring it meets specific regulatory requirements for testing in New York State.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration (FDA), although it follows CAP and CLIA regulations for clinical laboratory testing. Technical limitations include potential false negatives or inability to detect all genetic variants, and interpretive limitations may arise without comprehensive clinical information. Results should be considered alongside clinical evaluations and other diagnostic procedures.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided